NCT04862455 2026-01-23
NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
Clinical Trials
9 trialsNCT03539198 2024-11-14
Study of Proton SBRT and Immunotherapy for Recurrent/Progressive Locoregional or Metastatic Head and Neck Cancer
Mayo Clinic
Terminated
NCT04220775 2024-11-07
Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT03618134 2023-11-18
Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner
Jonsson Comprehensive Cancer Center
Phase 1/2 Terminated
NCT03522584 2023-06-12
Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
University of Washington
Phase 1/2 Terminated
NCT03402737 2021-02-18
SBRT + Immunomodulating Systemic Therapy for Inoperable, Recurrent H&N
University Hospital, Ghent
Phase NA Terminated
NCT02110992 2019-11-25
Safety Study of SBRT and Docetaxel for Locally Recurrent or Second Primary Squamous Cell Carcinoma of the Head and Neck
University of Cincinnati
Phase 1 Terminated
NCT02388932 2019-01-24
Stereotactic Body Radiation Therapy in Treating Patients With High Risk Locally Advanced Head and Neck Cancer
Case Comprehensive Cancer Center
Phase NA Terminated
NCT00891904 2016-04-14
Radiation Therapy and Cetuximab in Treating Patients With Recurrent Head and Neck Cancer
Roswell Park Cancer Institute
Phase NA Terminated